The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.
Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery
Population Health Strategies Are Vital for Tackling, Improving CKD Care
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden
Defragmentation of Care in Complex Patients With ESKD Improves Clinical Outcomes
An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease, and the methods of treatment used on the patient populations.
Results From the STEP Trial in China
Unmet Needs in the Management of Heart Failure
Results From the EMPEROR-Pooled Analysis
Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF
Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors
Practical Implications of the FIDELITY Pooled Analysis
Results From the FIDELITY Pooled Analysis
An Overview of the FIDELITY Pooled Analysis Design
Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD
An Overview of the FIGARO-DKD Trial Design
UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care
Current Status of Chronic Kidney Disease in the US
Navigating CKD Treatment Among Comorbidities
Dr Kirsten Johansen on Benefits of Oral Therapies for the Management of CKD
Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
Closing Thoughts on CKD Management
Continued Health Disparities Seen in Practice
Combination Therapy and Payer Perspective on CKD Therapies
Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management
The Role of MRAs in CKD and CV Treatment
Engage, Educate, Empower: Transforming Kidney Care
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
Advocating for All Patients With Chronic Kidney Disease
Managing Disparities in Chronic Kidney Disease Through Value-Based Arrangements
Examining the Shift to Value-Based Kidney Care Delivery in 2021
New Clinical Guidelines Recommend Finerenone for CKD Associated With T2D